Novo Nordisk announced today that Health Canada has issued marketing authorization with conditions [Notice of Compliance with ...

Learn about semaglutide’s effectiveness and clinical trial results and whether it could be right for you in your MASH treatment plan.

Roughly 1 in 3 adults has metabolic dysfunction–associated steatotic liver disease, or MASLD. A doctor outlines how to detect and slow the condition early.

Novo Nordisk’s Wegovy® (semaglutide 2.4 mg) was associated with liver health–related benefits not solely driven by weight ...

Altimmune, Inc. nears key MASH data for pemvidutide—learn investor risks, potential rewards, and what the upcoming results ...

Can Novo Nordisk get its comeback going in 2026? Let's discuss two things that could materialize for the company next year ...

Every year in biopharma brings its share of grueling defeats, and 2025 was no different, especially for companies targeting ...

We knew that GLP-1 drugs like Ozempic and Wegovy did more than just help control type 2 diabetes and aid weight loss, but the ...

Groundbreaking Harvard research reveals gut-produced molecules significantly influence obesity and blood sugar control. These ...

For more than two years it had the entirety of the market for weight-loss drugs to itself. By 2023 sales of Wegovy had ...

Even so, in an interview with The Economist, Mr Doustdar sounded confident that Novo can recover. His prescription is to push ...

This follows recent successful efforts by the Trump administration to cut the price of this compound for certain patients.